Overview

Safety and Tolerability of BVS857 in Subjects With Insulin Resistance

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The study will assess the safety, tolerability, drug label and effect in subjects with and without insulin resistance.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Insulin